Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CRO

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

Amgen says romosozumab on track for 2016 filing

Reports ‘significant’ reduction of fractures in post-menopausal osteoporosis patients

- PMLiVE

A five-step plan for patient-centred digital communications

Every functional area should be able to interact with patients

- PMLiVE

Reflections on marketing excellence

Looking back over 20 years of change in pharma marketing

- PMLiVE

Truly, madly, cheaply

The ongoing rhetoric of patient-centricity

- PMLiVE

Challenging perceptions

Alvaro Herreros on the ADHD landscape

Not as we know it

We shouldn’t expect our descendants to look like us

- PMLiVE

AZ cancer immunotherapy combo impresses in lung cancer trial

Durvalumab and tremelimumab combination show 'encouraging' efficacy signs

Daiichi Sankyo logo

Daiichi Sankyo begins sharing clinical trial data online

Joins the likes of GSK, Lilly, UCB and Astellas in opening up its records

- PMLiVE

Tresiba safer than insulin glargine, says Novo Nordisk

Trial compares its basal insulin with Sanofi's Lantus

- PMLiVE

Alkermes depression drug misses targets in phase III

Irish firm suffers major research setback with ALKS 5461

- PMLiVE

French government begins investigation into fatal Biotrial study

First-in-man trial leaves one dead, five hospitalised

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links